The Clinical Study of CD19 UCAR-T Cells in Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL)

Shanghai Longyao Biotechnology

Status and phase: Unknown; Early Phase 1

Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL); Safety and Efficacy of CD19 UCAR-T Cells

Treatments: Biological: CD19 UCARTcells

Study type: Interventional

Funder types: Other

Identifiers

NCT04166838

V1.0

Details and patient eligibility

About

This is a single arm, open-label, single center, exploratory clinical study to evaluate the safety and efficacy of CD19 UCAR-T Cells in Patients With CD19+ B-cell acute lymphoblastic leukemia (B-ALL).

Full description

This study did not set up a control group. The maximum dose was determined according to the dose escalation test. Based on the number of CART cells per kg body weight which was proved to be safe and effective, all the subjects were treated with one single dose of CD19 UCART cells per treatment course. The dose escalation test was designed to evaluate the three dose levels of CD19 UCART (1 × 10 ^ 6 cells/kg,3 × 10 ^ 6 cells/kg,5 × 10 ^ 6 cells/kg). Each CD19 UCART infusion will be carried out on day 0. Each subject was observed for at least 4 weeks after the last infusion. If there was no dose-limited toxicity (DLT), it is necessary to continue multiple treatment courses at this dose level. The detailed administration time and dose were decided by the researchers.

Enrollment: 20 estimated patients

Sex: All

Ages: 6 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 1. Subjects between 6 and 70 years of age, inclusive.

• 2. Subjects diagnosed as relapsed or refractory B cell acute lymphocytic leukemia (B-ALL):

  3. Relapse as defined by 2nd or greater BM relapse or Any BM relapse after allogeneic SCT, naive lymphocytes in BM≥5%；

  4. refractory as defined by not achieving a CR after 2 rounds of standard chemotherapy.

• 3. Life expectancy > 12 weeks.
• 4. ECOG score between 0 and 1.

• 5. Liver, Renal, Heart and Lungs function defined as:

  6. Creatininec≤1.5 ULN;

  7. ALT/AST ≤2.5 ULN;

  8. Total Bilirubin≤1.5×ULN;

  9. Pulse oxygenation≥92%;

  10. Left Ventricular Shortening Fraction (LVSF)≥50%;

• 6. Subjects could comprehend the clinical study and able to provide written consent at the time of consent or assent.

Exclusion criteria

• 1. Pregnant or lactating women, or men or women with pregnancy plans within 6 months.
• 2. Subjects with contagious disease，such as HIV, active HBV and HCV, and syphilis, etc.
• 3. Subjects with mental or psychological illness who cannot be combined with treatment and efficacy evaluation.
• 4. Subjects with severe autoimmune disease and long-term use of immunosuppressants.
• 5. Subjects with active or uncontrollable infections requiring systemic treatment within 14 days prior to enrollment.
• 6. Subjects with any unstable systemic disease including, but not limited to, active infection (except for local infection), unstable angina pectoris, cerebrovascular accident or transient cerebral ischemia (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ III).
• 7. subjects combined with dysfunction of vital organs such as lung, brain and kidney.
• 8. subjects that Participated in other similar clinical trials within 6 months.
• 9. subjects currently receiving treatment for other gene therapy.
• 10. subjects combined with graft versus host disease (GVHD).
• 11. Other subjects judged by the researchers to be unsuitable for admission to the study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

CD19 UCAR-T

Experimental group

Treatment:

Biological: CD19 UCARTcells